Skip to content

Study · Animal study (in vivo) · mouse · 2007

7 results

Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease.

Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E

Acta neuropathologica28 Nov 2006Cited by 73 (Europe PMC)

PMID17131129 (opens in a new tab)DOI10.1007/s00401-006-0166-5 (opens in a new tab)PepBankPUB-17131129
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In APP transgenic mice, CBL increased BrdU-positive cells compared with vehicle treatment.

    In plain wordsIn mice with an Alzheimer disease model, CBL increased BrdU-positive cells compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBrdU-positive cells
    Study

    mousen: not reported in source

    APP transgenic mice
    Comparator
    Vehicle-treated APP tg mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 and 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, APP tg mice treated with CBL showed a significant increase in BrdU+ cells, DCX+ neuroblasts and a decrease in TUNEL+ and activated caspase-3 immunoreactive NPC.
    1 context sentence
    Summary · context
    To study this possibility, tg mice expressing mutant APP under the Thy-1 promoter were injected with BrdU and treated with CBL for 1 and 3 months.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In APP transgenic mice, CBL increased DCX-positive neuroblasts compared with vehicle treatment.

    In plain wordsIn mice with an Alzheimer disease model, CBL increased DCX-positive immature neurons compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDCX-positive neuroblasts
    Study

    mousen: not reported in source

    APP transgenic mice
    Comparator
    Vehicle-treated APP tg mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 and 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, APP tg mice treated with CBL showed a significant increase in BrdU+ cells, DCX+ neuroblasts and a decrease in TUNEL+ and activated caspase-3 immunoreactive NPC.
    1 context sentence
    Summary · context
    To study this possibility, tg mice expressing mutant APP under the Thy-1 promoter were injected with BrdU and treated with CBL for 1 and 3 months.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, CBL decreased TUNEL-positive neural progenitor cells compared with vehicle treatment.

    In plain wordsIn mice with an Alzheimer disease model, CBL reduced TUNEL-positive neural progenitor cells compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTUNEL-positive neural progenitor cells
    Study

    mousen: not reported in source

    APP transgenic mice
    Comparator
    Vehicle-treated APP tg mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 and 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, APP tg mice treated with CBL showed a significant increase in BrdU+ cells, DCX+ neuroblasts and a decrease in TUNEL+ and activated caspase-3 immunoreactive NPC.
    1 context sentence
    Summary · context
    To study this possibility, tg mice expressing mutant APP under the Thy-1 promoter were injected with BrdU and treated with CBL for 1 and 3 months.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In APP transgenic mice, CBL decreased activated caspase-3 immunoreactive neural progenitor cells compared with vehicle treatment.

    In plain wordsIn mice with an Alzheimer disease model, CBL reduced progenitor cells with activated caspase-3 compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseActivated caspase-3 immunoreactive progenitor cells
    Study

    mousen: not reported in source

    APP transgenic mice
    Comparator
    Vehicle-treated APP tg mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 and 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, APP tg mice treated with CBL showed a significant increase in BrdU+ cells, DCX+ neuroblasts and a decrease in TUNEL+ and activated caspase-3 immunoreactive NPC.
    1 context sentence
    Summary · context
    To study this possibility, tg mice expressing mutant APP under the Thy-1 promoter were injected with BrdU and treated with CBL for 1 and 3 months.
  5. 05AnimalAnimal study (in vivo)Activity measurement

    In APP transgenic mice, CBL did not change the number of PCNA-positive neural progenitor cells compared with vehicle treatment.

    In plain wordsIn mice, CBL did not change PCNA-positive progenitor cell numbers compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changePCNA-positive progenitor cells
    Study

    mousen: not reported in source

    APP transgenic mice
    Comparator
    Vehicle-treated APP tg mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 and 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    CBL did not change the number of proliferating cell nuclear antigen+ (PCNA) NPC or the ratio of BrdU+ cells converting to neurons and astroglia in the SGZ cells in the APP tg mice.
    1 context sentence
    Summary · context
    To study this possibility, tg mice expressing mutant APP under the Thy-1 promoter were injected with BrdU and treated with CBL for 1 and 3 months.
  6. 06AnimalAnimal study (in vivo)Activity measurement

    In APP transgenic mice, CBL did not change the ratio of BrdU-positive cells converting to neurons compared with vehicle treatment.

    In plain wordsIn mice, CBL did not change the proportion of BrdU-positive cells becoming neurons compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBrdU-positive cell conversion to neurons
    Study

    mousen: not reported in source

    APP transgenic mice
    Comparator
    Vehicle-treated APP tg mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 and 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    CBL did not change the number of proliferating cell nuclear antigen+ (PCNA) NPC or the ratio of BrdU+ cells converting to neurons and astroglia in the SGZ cells in the APP tg mice.
    1 context sentence
    Summary · context
    To study this possibility, tg mice expressing mutant APP under the Thy-1 promoter were injected with BrdU and treated with CBL for 1 and 3 months.
  7. 07AnimalAnimal study (in vivo)Activity measurement

    In APP transgenic mice, CBL did not change the ratio of BrdU-positive cells converting to astroglia compared with vehicle treatment.

    In plain wordsIn mice, CBL did not change the proportion of BrdU-positive cells becoming astroglia compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBrdU-positive cell conversion to astroglia
    Study

    mousen: not reported in source

    APP transgenic mice
    Comparator
    Vehicle-treated APP tg mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 and 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    CBL did not change the number of proliferating cell nuclear antigen+ (PCNA) NPC or the ratio of BrdU+ cells converting to neurons and astroglia in the SGZ cells in the APP tg mice.
    1 context sentence
    Summary · context
    To study this possibility, tg mice expressing mutant APP under the Thy-1 promoter were injected with BrdU and treated with CBL for 1 and 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.